Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Delayed Quote USD

United Therapeutics Corporation (UTHR)

Compare
279.69
-12.03
(-4.12%)
At close: April 8 at 4:00:00 PM EDT
280.00
+0.31
+(0.11%)
Pre-Market: 6:39:18 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,877,400
2,877,400
2,327,500
1,936,300
1,685,500
Cost of Revenue
309,700
309,700
257,500
151,600
122,500
Gross Profit
2,567,700
2,567,700
2,070,000
1,784,700
1,563,000
Operating Expense
1,119,600
1,119,600
885,100
805,000
1,007,100
Operating Income
1,448,100
1,448,100
1,184,900
979,700
555,900
Net Non Operating Interest Income Expense
156,200
156,200
103,400
12,800
-1,900
Other Income Expense
-65,300
-65,300
-14,000
-41,900
39,900
Pretax Income
1,539,000
1,539,000
1,274,300
950,600
593,900
Tax Provision
343,900
343,900
289,500
223,300
118,100
Net Income Common Stockholders
1,195,100
1,195,100
984,800
727,300
475,800
Diluted NI Available to Com Stockholders
1,195,100
1,195,100
984,800
727,300
475,800
Basic EPS
26.44
26.44
21.04
15.98
10.60
Diluted EPS
24.64
24.64
19.81
15.00
10.06
Basic Average Shares
45,200
45,200
46,800
45,500
44,900
Diluted Average Shares
48,500
48,500
49,700
48,500
47,300
Total Operating Income as Reported
1,377,000
1,377,000
1,184,900
979,700
555,900
Total Expenses
1,429,300
1,429,300
1,142,600
956,600
1,129,600
Net Income from Continuing & Discontinued Operation
1,195,100
1,195,100
984,800
727,300
475,800
Normalized Income
1,250,558
1,250,558
984,800
728,609
477,640
Interest Income
199,100
199,100
162,700
45,200
16,700
Interest Expense
42,900
42,900
59,300
32,400
18,600
Net Interest Income
156,200
156,200
103,400
12,800
-1,900
EBIT
1,581,900
1,581,900
1,333,600
983,000
612,500
EBITDA
1,654,400
1,654,400
1,386,800
1,034,300
662,400
Reconciled Cost of Revenue
309,700
309,700
257,500
151,600
122,500
Reconciled Depreciation
72,500
72,500
53,200
51,300
49,900
Net Income from Continuing Operation Net Minority Interest
1,195,100
1,195,100
984,800
727,300
475,800
Total Unusual Items Excluding Goodwill
-71,100
-71,100
--
-1,700
-2,300
Total Unusual Items
-71,100
-71,100
--
-1,700
-2,300
Normalized EBITDA
1,725,500
1,725,500
1,386,800
1,036,000
664,700
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-15,642
-15,642
--
-391
-460
12/31/2021 - 6/17/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LQDA Liquidia Corporation
11.99
-3.54%
 
BMRN BioMarin Pharmaceutical Inc.
55.89
-5.53%
 
MNKD MannKind Corporation
4.6200
-1.49%
 
INSM Insmed Incorporated
64.97
-4.58%
 
EXEL Exelixis, Inc.
34.13
-2.04%
 
NBIX Neurocrine Biosciences, Inc.
87.54
-6.12%
 
ALNY Alnylam Pharmaceuticals, Inc.
224.32
-3.70%
 
HALO Halozyme Therapeutics, Inc.
57.54
-3.05%
 
ARGX argenx SE
548.93
-0.19%
 
REGN Regeneron Pharmaceuticals, Inc.
556.81
-2.79%